[go: up one dir, main page]

PE20211644A1 - Compuestos para tratar ciertas leucemias - Google Patents

Compuestos para tratar ciertas leucemias

Info

Publication number
PE20211644A1
PE20211644A1 PE2021000343A PE2021000343A PE20211644A1 PE 20211644 A1 PE20211644 A1 PE 20211644A1 PE 2021000343 A PE2021000343 A PE 2021000343A PE 2021000343 A PE2021000343 A PE 2021000343A PE 20211644 A1 PE20211644 A1 PE 20211644A1
Authority
PE
Peru
Prior art keywords
alkyl
leukemia
protein
compounds
abl1
Prior art date
Application number
PE2021000343A
Other languages
English (en)
Inventor
F Anthony Romero
Thorsten A Kirschberg
Randall Halcomb
Yiingzi Xu
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of PE20211644A1 publication Critical patent/PE20211644A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta referido a un compuesto de la formula (I) o (Ia), en donde: R1 es arilo, heteroarilo, entre otras opciones; R2 es H, alquilo, cicloalquilo, heterocicloalquilo, entre otras opciones; R3 es H, alquilo, alquenilo, alquinilo, cicloalquilo, entre otros; R4 es alquilo, alquenilo o alquinilo; L es -NH-CO-, -CO-NH-, -NH-SO2-, o -SO2-NH-; X es O, S; Y es CH, C-(alquilo C1-C2), C-halo o N; Z es CR5 o N. Estos compuestos inhiben la actividad enzimatica de tirosina quinasa de una proteina seleccionada de la proteina Abelson (ABL1), proteina relacionada con Abelson (ABL2), o una proteina quimerica BCR-ABL1, por lo que se les emplea en el tratamiento de la leucemia, principalmente la leucemia mieloide cronica (CML), leucemia mieloide aguda (AML), o leucemia linfoblastica aguda (ALL).
PE2021000343A 2018-09-18 2019-09-17 Compuestos para tratar ciertas leucemias PE20211644A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862733029P 2018-09-18 2018-09-18
US201962816637P 2019-03-11 2019-03-11
US201962889929P 2019-08-21 2019-08-21
PCT/US2019/051567 WO2020061086A2 (en) 2018-09-18 2019-09-17 Compounds for treating certain leukemias

Publications (1)

Publication Number Publication Date
PE20211644A1 true PE20211644A1 (es) 2021-08-24

Family

ID=69774840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000343A PE20211644A1 (es) 2018-09-18 2019-09-17 Compuestos para tratar ciertas leucemias

Country Status (19)

Country Link
US (4) US10889571B2 (es)
EP (1) EP3852745A4 (es)
JP (2) JP7611832B2 (es)
KR (1) KR20210061377A (es)
CN (3) CN112770745B (es)
AU (2) AU2019342102B2 (es)
BR (1) BR112021004051A2 (es)
CA (1) CA3110576A1 (es)
CL (1) CL2021000637A1 (es)
CO (1) CO2021004704A2 (es)
IL (2) IL322515A (es)
MA (1) MA53664A (es)
MX (2) MX2021003093A (es)
NZ (1) NZ773110A (es)
PE (1) PE20211644A1 (es)
SG (1) SG11202102367TA (es)
TW (1) TWI826525B (es)
WO (1) WO2020061086A2 (es)
ZA (1) ZA202101304B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10889571B2 (en) 2018-09-18 2021-01-12 Terns, Inc. Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias
SI3860998T1 (sl) 2018-10-05 2024-06-28 Annapurna Bio Inc. Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
TW202118756A (zh) * 2019-07-29 2021-05-16 大陸商蘇州亞盛藥業有限公司 作為ｂｃｒ－ａｂｌ抑制劑的雜環化合物
EP4017875A4 (en) 2019-08-23 2023-05-03 Terns Pharmaceuticals, Inc. THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
JP2022548250A (ja) 2019-09-12 2022-11-17 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
CA3212130A1 (en) * 2021-03-03 2022-09-09 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN116375650B (zh) * 2022-12-30 2025-08-05 浙江美诺华药物化学有限公司 一种替戈拉生中间体的制备方法
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
US20250090530A1 (en) 2023-08-31 2025-03-20 Terns Pharmaceuticals, Inc. Combinations for the treatment of cancer
WO2025226724A1 (en) 2024-04-23 2025-10-30 Terns Pharmaceuticals, Inc. Bcr-abl1 inhibitors for use in treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139828A0 (en) 1998-05-22 2002-02-10 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AR053364A1 (es) * 2005-04-20 2007-05-02 Smithkline Beecham Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
CN101553468A (zh) * 2006-10-18 2009-10-07 诺瓦提斯公司 有机化合物
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
WO2013033093A1 (en) 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
SG11201407152XA (en) 2012-05-15 2014-11-27 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA028626B1 (ru) 2012-06-11 2017-12-29 Юсб Байофарма Спрл БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α
CN103113355B (zh) 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
GB201401086D0 (en) 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
CN109790144A (zh) 2016-04-29 2019-05-21 爱仕达生物技术有限责任公司 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
JP6778833B2 (ja) 2017-01-20 2020-11-04 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物
WO2018133827A1 (zh) 2017-01-20 2018-07-26 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
US11649218B2 (en) 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
US10889571B2 (en) 2018-09-18 2021-01-12 Terns, Inc. Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias
EP4329749A4 (en) 2021-04-27 2025-03-19 Merck Sharp & Dohme LLC SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT
US20240400582A1 (en) 2021-09-30 2024-12-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Four-membered fused ring compound and preparation method and use thereof
KR20260004344A (ko) 2023-03-30 2026-01-08 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 4차 융합 고리 화합물의 염 결정 형태, 및 이의 제조 방법 및 이의 용도
US20250090530A1 (en) 2023-08-31 2025-03-20 Terns Pharmaceuticals, Inc. Combinations for the treatment of cancer

Also Published As

Publication number Publication date
CL2021000637A1 (es) 2021-10-01
US20240101536A1 (en) 2024-03-28
MX2021003093A (es) 2021-05-12
US12454524B2 (en) 2025-10-28
CN112770745B (zh) 2022-09-02
WO2020061086A3 (en) 2020-07-23
TW202024037A (zh) 2020-07-01
CO2021004704A2 (es) 2021-04-30
ZA202101304B (en) 2024-09-25
IL322515A (en) 2025-10-01
WO2020061086A2 (en) 2020-03-26
MX2023007714A (es) 2023-07-10
AU2024287115A1 (en) 2025-01-16
JP2025066704A (ja) 2025-04-23
IL281427A (en) 2021-04-29
BR112021004051A2 (pt) 2021-05-25
TWI826525B (zh) 2023-12-21
CN115448908A (zh) 2022-12-09
US20200087283A1 (en) 2020-03-19
US20250243184A1 (en) 2025-07-31
AU2019342102B2 (en) 2024-10-03
IL281427B2 (en) 2026-01-01
CN115215838B (zh) 2025-04-04
JP2022501429A (ja) 2022-01-06
KR20210061377A (ko) 2021-05-27
SG11202102367TA (en) 2021-04-29
AU2019342102A1 (en) 2021-03-11
JP7611832B2 (ja) 2025-01-10
EP3852745A2 (en) 2021-07-28
US20250276961A1 (en) 2025-09-04
IL281427B1 (en) 2025-09-01
MA53664A (fr) 2022-05-04
CA3110576A1 (en) 2020-03-26
CN115215838A (zh) 2022-10-21
US12240835B2 (en) 2025-03-04
NZ773110A (en) 2024-11-29
US10889571B2 (en) 2021-01-12
CN115448908B (zh) 2025-04-25
EP3852745A4 (en) 2022-05-04
CN112770745A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
PE20211644A1 (es) Compuestos para tratar ciertas leucemias
PE20210004A1 (es) Inhibidores de mcl-1
CL2020003219A1 (es) Compuestos
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
MX388751B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
ATE446752T1 (de) Hemmer der akt aktivität
ATE512957T1 (de) Hemmer der akt aktivität
PE20181803A1 (es) Inhibidores de mcl-1 macrociclicos para tratar el cancer
MX2016003239A (es) Pesticidas de azoles biciclicos sustituidos con heterociclos.
SA523440283B1 (ar) مركبات مضادة للأورام
EA201992322A2 (ru) Соединения и композиции для лечения гематологических расстройств
PE20190912A1 (es) Compuesto de piridona como inhibidor de c-met
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
CL2016002033A1 (es) Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros.
UA107804C2 (en) Mixtures of pesticides mezoionnyh
ECSP056072A (es) Pirimidinonas sustituidas
PE20220281A1 (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
EA201892815A1 (ru) Новые антибактериальные соединения
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
GEAP202516632A (en) Heteroaryl compounds for the treatment of pain
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
MD20230027A2 (ro) Amestecuri de pesticide cu conţinut de indazoli
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
MX2022000243A (es) Nuevos compuestos heterociclicos.